Unknown

Dataset Information

0

ABT-333 (Dasabuvir) Increases Action Potential Duration and Provokes Early Afterdepolarizations in Canine Left Ventricular Cells via Inhibition of IKr.


ABSTRACT: ABT-333 (dasabuvir) is an antiviral agent used in hepatitis C treatment. The molecule, similarly to some inhibitors of hERG channels, responsible for the delayed rectifier potassium current (IKr), contains the methanesulfonamide group. Reduced IKr current leads to long QT syndrome and early afterdepolarizations (EADs), therefore potentially causing life-threatening arrhythmias and sudden cardiac death. Our goal was to investigate the acute effects of ABT-333 in enzymatically isolated canine left ventricular myocardial cells. Action potentials (APs) and ion currents were recorded with a sharp microelectrode technique and whole-cell patch clamp, respectively. Application of 1 μM ABT-333 prolonged the AP in a reversible manner. The maximal rates of phases 0 and 1 were irreversibly decreased. Higher ABT-333 concentrations caused larger AP prolongation, elevation of the early plateau potential, and reduction of maximal rates of phases 0, 1, and 3. EADs occurred in some cells in 3-30 μM ABT-333 concentrations. The 10 μM ABT-333-sensitive current, recorded with AP voltage clamp, contained a late outward component corresponding to IKr and an early outward one corresponding to transient outward potassium current (Ito). ABT-333 reduced hERG-channel-mediated ion current in a concentration-dependent, partially reversible manner with a half-inhibitory concentration of 3.2 μM. As the therapeutic plasma concentration of ABT-333 is 1 nM, the arrhythmic risk of ABT-333 is very low, even in the case of drug overdose.

SUBMITTER: Kovacs ZM 

PROVIDER: S-EPMC10143825 | biostudies-literature | 2023 Mar

REPOSITORIES: biostudies-literature

altmetric image

Publications

ABT-333 (Dasabuvir) Increases Action Potential Duration and Provokes Early Afterdepolarizations in Canine Left Ventricular Cells via Inhibition of I<sub>Kr</sub>.

Kovács Zsigmond Máté ZM   Óvári József J   Dienes Csaba C   Magyar János J   Bányász Tamás T   Nánási Péter P PP   Horváth Balázs B   Feher Adam A   Varga Zoltan Z   Szentandrássy Norbert N  

Pharmaceuticals (Basel, Switzerland) 20230325 4


ABT-333 (dasabuvir) is an antiviral agent used in hepatitis C treatment. The molecule, similarly to some inhibitors of hERG channels, responsible for the delayed rectifier potassium current (I<sub>Kr</sub>), contains the methanesulfonamide group. Reduced I<sub>Kr</sub> current leads to long QT syndrome and early afterdepolarizations (EADs), therefore potentially causing life-threatening arrhythmias and sudden cardiac death. Our goal was to investigate the acute effects of ABT-333 in enzymaticall  ...[more]

Similar Datasets

| S-EPMC6363420 | biostudies-literature
| S-EPMC2993199 | biostudies-literature
| S-EPMC3936372 | biostudies-literature
| S-EPMC3888406 | biostudies-literature
| S-EPMC6613166 | biostudies-literature
| S-EPMC3749940 | biostudies-literature
| S-EPMC2042930 | biostudies-other
| S-EPMC8983343 | biostudies-literature
| S-EPMC2826175 | biostudies-literature
| S-EPMC9214609 | biostudies-literature